Department of Pathology, Chungnam National University School of Medicine, Daejeon, Korea
© 2022 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Clinicopathologic findings | GEA (n = 10) | UEA (n = 12) |
---|---|---|
Age (yr) | ||
Mean ± SD | 61.7 ± 11.9 | 45.3 ± 10.9 |
Range | 48–80 | 31–68 |
Type of surgical treatment | ||
Radical hysterectomy | 7 (70.0) | 8 (66.7) |
Total hysterectomy | 0 | 3 (25.0) |
Trachelectomy | 1 (10.0) | 0 |
Conization | 2 (20.0) | 1 (8.3) |
FIGO stage | ||
I | 1 (10.0) | 9 (75.0) |
II | 4 (40.0) | 1 (8.3) |
III | 3 (30.0) | 2 (16.7) |
IV | 2 (20.0) | 0 |
Human papillomavirus status | ||
High-risk HPV | 0 | 12 (100) |
Not detected | 10 (100) | 0 |
p16 expression | ||
Block positive | 1 (10.0) | 12 (100) |
Patchy positive/negative | 9 (90.0) | 0 |
p53 expression | ||
Diffuse strong positive | 5 (50.0) | 0 |
Complete loss (null) | 1 (10.0) | 0 |
Patchy positive | 4 (40.0) | 12 (100) |
Follow-up results | ||
No evidence of disease | 2 (20.0) | 9 (75.0) |
Alive with disease | 3 (30.0) | 0 (0.0) |
Died of disease | 4 (40.0) | 0 (0.0) |
Died of other disease | 0 | 1 |
Not available | 1 (10.0) | 2 (16.7) |
Case No. | Age (yr) | Preparation type | Cytologic diagnosis | Type of surgery | FIGO stage | HPV | p16 | p53 | MUC-6 | Adjuvant treatment | Follow-up (mo) | Outcome | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||
CS | LBP | ||||||||||||
1 | 48 | + | + | AIS | Trachelectomy | IVA | − | − | + | + | CC | 20 | DOD |
2 | 80 | + | + | Adenocarcinoma | RH | IIB | − | − | Wild | − |
RT | 38 | DOD |
3 | 52 | + | + | AGC | RH | IIIC1 | − | − | Wild | + | CCRT | 48 | AWD |
4 | 58 | + | + | Adenocarcinoma | RH | IVA | − |
− | + | + | CC | 23 | DOD |
5 | 54 | + | + | Adenocarcinoma | RH | IIA1 | − | + | + | + | NA | FU loss | NA |
6 | 54 | NA | NA | NA | Conization | IIIC1 | − | − | Wild | + | CCRT | 17 | DOD |
7 | 78 | NA | + | Adenocarcinoma | Conization | IIA2 | − | − | + | − |
RT | 21 | NED |
8 | 63 | NA | + | AGC | RH | IB1 | − | − | Null | + | CCRT | 21 | NED |
9 | 76 | NA | + | AGC | RH | IIB | − | − | + | + | RT | 10 | AWD |
10 | 54 | NA | NA | NA | RH | IIIC1 | − | − | Wild | + | CCRT | 10 | AWD |
Cytologic finding | GEA (n=8) | UEA (n=12) | p-value |
---|---|---|---|
Mucinous background | .058 | ||
Absent | 2 (25.0) | 2 (16.7) | |
Focal | 2 (25.0) | 9 (75.0) | |
Extensive | 4 (50.0) | 1 (8.3) | |
Architecture | |||
Monolayered honeycomb-like sheet | .002 | ||
Absent | 0 | 6 (50.0) | |
Focal | 1 (12.5) | 5 (41.7) | |
Extensive | 7 (87.5) | 1 (8.3) | |
3-dimensional clusters | .010 | ||
Absent | 0 | 0 | |
Focal | 5 (62.5) | 1 (8.3) | |
Extensive | 3 (37.5) | 11 (91.7) | |
Feathering | .189 | ||
Absent | 3 (37.5) | 3 (25.0) | |
Focal | 5 (62.5) | 5 (41.7) | |
Extensive | 0 | 4 (33.3) | |
Nuclei | |||
Vesicular nuclei | .057 | ||
Absent | 0 (0.0) | 1 (8.3) | |
Focal | 0 (0.0) | 5 (41.7) | |
Extensive | 8 (100.0) | 6 (50.0) | |
Hyperchromasia | .082 | ||
Absent | 2 (25.0) | 0 | |
Focal | 6 (75.0) | 9 (75.0) | |
Extensive | 0 (0.0) | 3 (25.0) | |
Nuclear groove | .230 | ||
Absent | 0 (0.0) | 3 (25.0) | |
Focal | 6 (75.0) | 8 (66.7) | |
Extensive | 2 (25.0) | 1 (8.3) | |
Nucleoli | .146 | ||
Absent | 0 (0.0) | 3 (25.0) | |
Focal | 3 (37.5) | 6 (50.0) | |
Extensive | 5 (62.5) | 3 (25.0) | |
Intranuclear pseudoinclusion | .761 | ||
Absent | 7 (87.5) | 11 (91.7) | |
Focal | 1 (12.5) | 1 (8.3) | |
Extensive | 0 | 0 | |
Cytoplasm | |||
Vacuolar/granular | .001 | ||
Absent | 0 | 2 (16.7) | |
Focal | 0 | 8 (66.7) | |
Extensive | 8 (100) | 2 (16.7) | |
Golden-brown mucin | .089 | ||
Absent | 3 (37.5) | 10 (83.3) | |
Focal | 4 (50.0) | 2 (16.7) | |
Extensive | 1 (12.5) | 0 | |
Neutrophils | .461 | ||
Absent | 0 | 1 (8.3) | |
Focal | 2 (25.0) | 5 (41.7) | |
Extensive | 6 (75.0) | 6 (50.0) |
Kawakami et al. [ |
Lu et al. [ |
Schwock et al. [ |
Ryu et al. [ |
This study | Total, n (%) | |
---|---|---|---|---|---|---|
No. of cases | 14 | 11 | 15 | 8 | 8 | 56 (100) |
Preparation type | CS | LBC | CS and LBC | CS and LBC | CS and/or LBC | CS and/or LBC |
TBS classification | ||||||
Unsatisfactory | 0 | 1 | 0 | 0 | 0 | 1 (1.8) |
NILM | 0 | 5 | 5 | 0 | 0 | 10 (17.9) |
AGC | 3 | 4 | 2 | 4 | 3 | 16 (28.6) |
AIS | 0 | 0 | 1 | 1 | 1 | 3 (5.4) |
HSIL | 0 | 1 | 0 | 0 | 0 | 1 (1.8) |
Adenocarcinoma | 11 | 0 | 7 | 3 | 4 | 25 (44.6) |
Values are presented as number (%) unless otherwise indicated. GEA, gastric-type endocervical adenocarcinoma; UEA, usual-type endocervical adenocarcinoma; SD, standard deviation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus. Died of stomach cancer.
CS, conventional smear; LBP, liquid-based preparation; FIGO, International Federation of Gynecology and Obstetrics; HPV, human papillomavirus; AIS, adenocarcinoma in situ; CC, combined chemotherapy; DOD, died of disease; RH, radical hysterectomy; RT, radiotherapy; AGC, atypical glandular cells, favor neoplastic; CCRT, combined chemotherapy and radiotherapy; AWD, alive with disease; NA, not available; FU, follow-up; NED, no evidence of disease. Pale pinkish-red cytoplasmic neutral mucin on Alcian blue/PAS special staining; High risk HPV DNA in situ hybridization; +, p16, block-type positivity; +, p53, overexpression.
GEA, gastric-type endocervical adenocarcinoma; CS, conventional smear; LBC, liquid-based cytology; TBS, The Bethesda System; NILM, negative for intraepithelial lesion or malignancy; AGC, atypical glandular cells, not otherwise specified and favor adenocarcinoma; AIS, adenocarcinoma in situ; HSIL, high-grade squamous intraepithelial lesion.